Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.75 USD
Change Today +0.07 / 2.61%
Volume 4.1K
CLRB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Open
$2.74
Previous Close
$2.68
Day High
$2.80
Day Low
$2.74
52 Week High
06/13/14 - $7.60
52 Week Low
10/20/14 - $1.76
Market Cap
20.8M
Average Volume 10 Days
15.5K
EPS TTM
$-1.83
Shares Outstanding
7.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLECTAR BIOSCIENCES INC (CLRB)

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a biopharmaceutical company, develops compounds for the treatment, diagnosis, and imaging of cancer. The company’s proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. It also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as completed Phase Ib dose-escalation trial for patients with advanced solid tumors. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $262.5K
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Chief Financial Officer, Vice President and T...
Total Annual Compensation: $127.9K
Vice President of Investor Relations, Public ...
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Reports Financial Results for the First Quarter Ended March 31, 2015; Provides Update on Clinical Programs

Cellectar Biosciences, Inc. reported financial results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $2.3 million or $0.30 per share versus a net loss of $2.9 million or $1.03 per share for the comparable period in 2014. The company provided clinical development program updates: I-124-CLR1404: After activating five large new centers this year, Cellectar has seen an increase in patient screening and anticipates a significant increase in enrollment in its Phase II trial of I-124-CLR1404 in glioblastoma. However, enrollment remains slower than expected and the company is evaluating potential strategies to leverage existing data from investigator-sponsored studies to modify its ongoing Phase II trial of I-124-CLR1404 in glioblastoma and reduce the time to successful trial completion. Progress in investigator-sponsored clinical trials of I-124-CLR1404, including imaging of 30 patients with various brain cancers, should provide meaningful evidence for the optimal dose and imaging time-point for the use of I-124-CLR1404 in glioblastoma, the primary objective of the on-going company-sponsored Phase II trial in glioblastoma. I-131-CLR1404: In April 2015, Cellectar initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma, an indication for which I-131-CLR1404 previously received orphan drug designation from the U.S. Food and Drug Administration. Based on data from the company's Phase Ib trial, Cellectar anticipates that evidence of clinical activity will be assessable relatively early in the dose escalation process. Cellectar continues to expect data from this program to be available by year-end 2015. CLR1502: In February 2015, a publication featured on the cover of Neurosurgery, Official Journal of the Congress of Neurological Surgeons - the large neurosurgical society in the world, demonstrated that Cellectar's fluorescent, cancer-selective agents successfully provide visualization of glioma cells with high fidelity, and suggest their practical and promising potential to optimize tumor surgery. During the first quarter of 2015, Cellectar submitted an investigational new drug (IND) application to the FDA to allow for initiation of a Phase I proof-of-concept trial of CLR1502 in breast cancer patients undergoing lumpectomy. The trial is intended to establish the safety and tolerability of CLR1502 while demonstrating its utility in the real-time identification of malignant tissue. Cellectar is currently working with the FDA to determine if CLR1502 should be evaluated as an imaging agent through the Center for Drug Evaluation and Research (CDER) or as a combination product along with an imaging system (light source) through the Center for Devices and Radiological Health (CDRH). Cellectar is working closely with the FDA to resolve this matter and expects to initiate its planned proof-of-concept study in the second half of 2015.

Cellectar Biosciences, Inc. announced delayed 10-Q filing

On 05/18/2015, Cellectar Biosciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Cellectar Biosciences, Inc., Q1 2015 Earnings Call, May 21, 2015

Cellectar Biosciences, Inc., Q1 2015 Earnings Call, May 21, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $2.75 USD +0.07

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies
 

Industry Analysis

CLRB

Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit www.cellectar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.